Molecular Details of Actinomycin D-Treated MRSA Revealed via High-Dimensional Data.

Xuewei Xia, Jun Liu, Li Huang, Xiaoyong Zhang, Yunqin Deng, Fengming Li, Zhiyuan Liu, Riming Huang

Marine drugs 2022 Jan 31

filter terms:

Methicillin-resistant Staphylococcus aureus (MRSA) is highly concerning as a principal infection pathogen. The investigation of higher effective natural anti-MRSA agents from marine Streptomyces parvulus has led to the isolation of actinomycin D, that showed potential anti-MRSA activity with MIC and MBC values of 1 and 8 μg/mL, respectively. Proteomics-metabolomics analysis further demonstrated a total of 261 differential proteins and 144 differential metabolites induced by actinomycin D in MRSA, and the co-mapped correlation network of omics, indicated that actinomycin D induced the metabolism pathway of producing the antibiotic sensitivity in MRSA. Furthermore, the mRNA expression levels of the genes acnA, ebpS, clfA, icd, and gpmA related to the key differential proteins were down-regulated measured by qRT-PCR. Molecular docking predicted that actinomycin D was bound to the targets of the two key differential proteins AcnA and Icd by hydrogen bonds and interacted with multiple amino acid residues of the proteins. Thus, these findings will provide a basic understanding to further investigation of actinomycin D as a potential anti-MRSA agent.

Citation

Xuewei Xia, Jun Liu, Li Huang, Xiaoyong Zhang, Yunqin Deng, Fengming Li, Zhiyuan Liu, Riming Huang. Molecular Details of Actinomycin D-Treated MRSA Revealed via High-Dimensional Data. Marine drugs. 2022 Jan 31;20(2)